Novo

Eli Lilly Enters the Obesity Battle: New Pill Poised to Challenge Novo Nordisk’s Oral Wegovy, Shaking Up the Weight Loss Market and Investor Landscape

Eli Lilly's obesity pill will rival Novo Nordisk's oral Wegovy drug

Eli Lilly’s Obesity Pill: Underwhelming Trial Data but a Potential Game-Changer in the Weight Loss Market Eli Lilly’s recent trial results for its obesity pill, orforglipron, sent its stock tumbling 13% initially, reflecting Wall Street’s … Read more

Novo Nordisk Slashes Price on Ozempic, Signaling Strategic Move to Broaden Diabetes Treatment Access and Boost Market Share—A Key Insight for Investors Eyeing Pharma Growth

Novo Nordisk offers diabetes drug Ozempic for steep cash discount

Novo Nordisk’s Bold Move on Ozempic Pricing: What Investors and Advisors Must Know Now Novo Nordisk just shook up the diabetes and obesity drug market with a game-changing pricing strategy for its blockbuster drug Ozempic. … Read more